Loading…
← CockpitCompetitor Analysis › 688581.SS Hangzhou AGS MedTech Co. Ltd.Open in the cockpit ↗

Hangzhou AGS MedTech Co. Ltd.688581.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum strong 64
Mkt cap
$590M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$4.92M
20-day average traded
Fwd P/E
18.9×
forward earnings
ROIC−WACC
+13.5 pp
WACC 7.8%
Hurdle
-27 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥48.88
1D+0.1%
1W-3.6%
1M-8.2%
3M-9.2%
6M-21.9%
YTD-16.6%
1Y-20.9%
ATR %3.3%
52w lowhigh34.3% off high

What Hangzhou AGS MedTech does

Employees: 807

Hangzhou AGS MedTech at a glance

Size Hangzhou AGS MedTech (688581.SS) is a China Health Care company (Medical Specialties) with a market value of $590M, the 3292nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥48.88 on 18 Nov 2026.

Performance Over six months the shares fell 21.9%, against -2.1% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 19 in its peer set.

Growth Revenue fell 18.1% over the last twelve months (peer median +14.4%); the operating margin is 32.6% (peer median 7.4%).

Valuation It trades at 18.9× forward earnings against a peer median of 27.7× (4th cheapest of 11).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -27 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.5 points above its cost of capital (7.8% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 98688581.SS 79
Six months, rebased to 100: Hangzhou AGS MedTech against the median of its 20 peers (local-currency closes).

Hangzhou AGS MedTech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥548MCN¥587MCN¥630MCN¥505MCN¥368M
Revenue growth—-7%+25%+37%—
Gross profitCN¥395MCN¥405MCN¥447MCN¥354MCN¥247M
EBITDAn/aCN¥226MCN¥292MCN¥223MCN¥157M
Net incomeCN¥188MCN¥222MCN¥293MCN¥217MCN¥145M
Free cash flowCN¥146MCN¥87.7MCN¥266MCN¥170MCN¥96.3M
Capital expenditureCN¥55.4MCN¥63.5MCN¥49.6MCN¥51.6MCN¥60.1M
Total debtCN¥72.4MCN¥54.9MCN¥10.6MCN¥11.9MCN¥6.71M

Quarterly statements and history in the cockpit →

Hangzhou AGS MedTech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%300314TCMDOBIOSGHTMEDINAN300952PACBXVIVO3012356882366031224728300869ZJYLMYGN688581.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Hangzhou AGS MedTech is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%50×100×300314TCMDMEDINAN300952XVIVO3012356882361789605369688581.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hangzhou AGS MedTech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%TCMDMEDINANXVIVO68823647283008691789605369688581.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hangzhou AGS MedTech is the large dot.

Hangzhou AGS MedTech competitors and peer comparison

How Hangzhou AGS MedTech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hangzhou AGS MedTech against its 20 peers (data as of 18 Nov 2026)
Measure688581.SSPeer medianRank in peer set
1-month return-8.2%-0.8%5th lowest of 19
6-month return-21.9%-2.1%8th lowest of 19
Distance from 52-week high-34.3%-32.7%10th lowest of 20
Revenue growth (TTM)-18.1%+14.4%lowest of 20
Operating margin32.6%7.4%2nd highest of 20
Forward P/E18.9×27.7×4th cheapest of 11
Growth the price implies (Req g, 7 yrs)0.4%8.4%5th least demanding of 10
Growth delivered (Del g)+27.8%+6.7%2nd highest of 10
Hurdle (Req g minus delivered)-27.5 pp-3.6 ppleast demanding of 10
ROIC minus cost of capital+13.5 pp-3.3 pp5th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
vVARDIS VVVVUnited States$594Mn/a+148%-72%n/an/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%n/an/an/a
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%33.7×n/an/a
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%17.4×-8.5%+2.2%
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%n/an/an/a
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%n/a15.0%-19.8%
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%23.5×10.2%+6.5%
Jin Medical International ZJYLUnited States$532M+47%-14%2%n/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%n/an/an/a

Questions

Which companies are Hangzhou AGS MedTech's closest peers?
The cockpit's peer set: Ningbo David Medical Device (300314.SZ), Tactile Systems Technology (TCMD), Orchestra BioMed (OBIO), vVARDIS (VVVV), Sahajanand Medical Technologies (SMT.NS), Sight Sciences (SGHT), Medistim (MEDI.OL), Nanosonics (NAN.AX).
Is Hangzhou AGS MedTech expensive compared with its peers?
On forward p/e it trades at 18.9× against a peer median of 27.7×, 4th cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -27 pp: the price already allows for a slowdown.
How has Hangzhou AGS MedTech stock performed?
Over six months to 18 Nov 2026 the shares returned -21.9% against -2.1% for the median peer; over one year -20.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.